Compare CETY & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CETY | CALC |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 9.7M |
| IPO Year | 2020 | 2020 |
| Metric | CETY | CALC |
|---|---|---|
| Price | $0.76 | $0.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 71.6K | ★ 130.4K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | ★ $957,633.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.81 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $0.46 |
| 52 Week High | $3.05 | $7.20 |
| Indicator | CETY | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 60.12 |
| Support Level | $0.68 | $0.52 |
| Resistance Level | $0.85 | $0.93 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 39.09 | 64.68 |
Clean Energy Technologies Inc is clean energy and environmentally sustainable technologies company offering heat recovery solutions products. In addition, it also provides engineering and manufacturing solutions focused on other energy-efficient and environmentally sustainable technologies. The company's principal product is the Clean Cycle generator, offered by Heat Recovery Solutions. The company's engineering and manufacturing resources support its heat recovery solutions business. It has four segments: Clean Energy HRS & CETY Europe, CETY Renewables Waste to Energy Solutions, Engineering and Manufacturing Business and CETY HK. It serves various markets, including industrial, aerospace, military, instrumentation, and medical.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.